Pfizer finishes enrolling children 12-15 in COVID-19 vaccine study
Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday.
Pfizer said the Phase 3 clinical trial began in late July 2020 and completed enrollment of 46,331 participants in January, including over 2,200 participants aged 12-15. The company also plans to study the vaccine in pregnant women, among other populations.
Vaccines from Pfizer and Moderna Inc. are not currently available for use in children due to a lack of studies. The Food and Drug Administration last month authorized emergency use of the vaccine for individuals age 16 and older.
Related News Articles
Headline
The Food and Drug Administration today authorized Pfizer’s COVID-19 vaccine for pediatric use, moving the issue of administration to the Centers for…
Headline
The American Medical Association this week published a Current Procedural Terminology code for providers administering a booster dose of the Johnson…
Headline
In a study of over 7,000 adults hospitalized with COVID-19 symptoms, unvaccinated patients with prior SARS-CoV-2 infection were five times more likely to have…
Headline
As a Centers for Disease Control and Prevention advisory committee prepares to consider expanding COVID-19 vaccine eligibility to children aged 5-11, the AHA,…
Headline
In a study comparing 6.4 million COVID-19 vaccine recipients with 4.6 million demographically similar unvaccinated persons, recipients of the Pfizer, Moderna…
Headline
The Equal Employment Opportunity Commission today posted updated and expanded technical assistance related to the COVID-19 pandemic, addressing questions…